Ross is a partner in the Corporate Technology & Life Sciences team, based in our Cambridge office.

Ross is a lead partner within the firm's Tier 1-ranked Biotechnology practice in Cambridge. His practice involves helping life sciences and technology companies as they progress through their life cycle in all aspects of their growth, capital raising and international expansion. As a sector specialist, Ross focuses on biotech, medical devices and diagnostics within Life Sciences, and with the Tech sector supports companies operating in the capital intensive deep tech space, including quantum computing, artificial intelligence, advanced materials, as well as web3.

Ross has extensive experience of a variety of venture and growth financing, public capital raisings, mergers and acquisitions and general corporate advice. Ross was based out of San Francisco, CA in 2018 – 19 and as a result, he has a particular expertise in transactions with a transatlantic component. He is an English qualified solicitor and registered foreign legal consultant in California.

CV ansehen CV ausblenden

The impact of affluence on the next economy

An international study examining the behaviours, motivations and goals of today’s UHNW individuals. 

Read full report

Aktuelle News & Insights

Gesellschaftsrecht/ M&A & Kapitalmärkte

The AIM market: guides for US issuers

27. April 2022

von mehreren Autoren

Klicken Sie hier für Details
Gesellschaftsrecht/ M&A & Kapitalmärkte

Advising New Science Ventures as lead investor on Paragraf's $60 million Series B funding round

4. März 2022

von Ross McNaughton und Adrian Toutoungi

Klicken Sie hier für Details
Gesellschaftsrecht/ M&A & Kapitalmärkte

Advising Placid0 on its acquisition by eyecare brand WALDO

25. Februar 2022

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Healthcare

Advising Nuclera on its Series B funding round

2. Februar 2022

von mehreren Autoren

Klicken Sie hier für Details

Meet me at

Alle Veranstaltungen und Webinare finden Sie auf unserer Event-Seite.